Skip to content
MARKETS / BALCAO / CFOR
BALCAO · SERVICES-MEDICAL LABORATORIES · SMALL CAP

CapForce Inc. CFOR

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$30.2M
▲ 481.2% YoY
$23.6M
▲ 97.0% YoY
$-1.2M
In brief

What this company does

In furtherance of such shift, the Company established a wholly-owned subsidiary, CapForce International Holdings Ltd. (“CapForce International”), which launched a new business line offering listing sponsorship and consultancy services to international companies seeking to list their securities on securities exchanges. Additionally, CapForce is entering the financial technology industry supporting digital investment banking activities and capital table management. CapForce offers capital market listing sponsorship services to mid-sized growth-stage private companies around the world targeting public market listings with market capitalization values between $1 billion and $10 billion.

Written from the business description in CapForce Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 May 2026. Every sentence was checked against that document before publication.

Growth
USD 30.2M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 30.2 · Net income 23.6
20M-20M2014201620182020202220242025
Compound annual growth
+126.3%
+48.3%
+25.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +48.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
78 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 79.6% · Net 78.2%
100%200%-500%-1000%2014201620182020202220242025
ROE
FY2025 · ROE 120.4%
50%100%-200%-400%-600%2014201620182020202220242025

Each USD of equity produced 120 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.2
-8M-16M2014201620182020202220242025

Total assetsUSD 38.1M
EquityUSD 31.9M
CashUSD 531,277.00
Current ratio0.22×

Equity funds 84% of total assets.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0··0.00.00.00.00.00.0−0.00.0
Net income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $2.322.30−41.47−152.70−22.89−1.66−7.70−44.49−9.80−27.59−2.20−16.25
Dividend / sh $············
Payout %············
ROE %120.4··−152.8−111.5−205.7−327.4−567.7−675.0−359.7··
Shares out B0.010.010.000.000.000.030.010.000.000.000.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 40 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image